{"DataElement":{"publicId":"4614091","version":"1","preferredName":"Platinum-Based Chemotherapy Stage I Stage II Stage IIIA Stage IIIB Disease or Disorder Prior Agent Received Text","preferredDefinition":"The free text field for the specification of a platinum-based chemotherapy used for Stage I-IIIB disease.","longName":"4614074v1.0:4273795v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"4614074","version":"1","preferredName":"Platinum-Based Chemotherapy Stage I Stage II Stage IIIA Stage IIIB Disease or Disorder","preferredDefinition":"The use of a platinum-based chemotherapy on Stage I-IIIB disease.","longName":"4614071v1.0:4614072v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"4614071","version":"1","preferredName":"Platinum-Based Chemotherapy","preferredDefinition":"Derived from or containing platinum.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.","longName":"C25620:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum-Based","conceptCode":"C25620","definition":"Derived from or containing platinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BA5810-B1B0-540A-E050-BB89AD431D80","latestVersionIndicator":"Yes","beginDate":"2014-11-25","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-25","modifiedBy":"ONEDATA","dateModified":"2014-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4614072","version":"1","preferredName":"Stage I Stage II Stage IIIA Stage IIIB Disease or Disorder","preferredDefinition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.:Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.:Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.):Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axilla","longName":"4614072v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I","conceptCode":"C27966","definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Stage II","conceptCode":"C28054","definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Stage IIIA","conceptCode":"C27977","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage IIIB","conceptCode":"C27978","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BA5810-B1C4-540A-E050-BB89AD431D80","latestVersionIndicator":"Yes","beginDate":"2014-11-25","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-25","modifiedBy":"ONEDATA","dateModified":"2014-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BA5810-B1D5-540A-E050-BB89AD431D80","latestVersionIndicator":"Yes","beginDate":"2014-11-25","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4273795","version":"1","preferredName":"Prior Agent Received Text","preferredDefinition":"The free text field for the prior therapeutic agent received by patient","longName":"4273795v1.0","context":"SWOG","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7353D91-EF61-9D8B-E040-BB89AD4328CC","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-16","modifiedBy":"KEARNSD","dateModified":"2014-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify","type":"Preferred Question Text","description":"Specify","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BDCB-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}